Commercial CoverageThe percent of commercial lives covered has increased to 60%, delivering an incremental 22 million covered lives, which should boost sales.
Intellectual PropertyThe dismissal of patent litigation and Sandoz's withdrawal of its ANDA for generic solriamfetol demonstrates the strength of Axsome's intellectual property and removes a potential generic threat.
Product LaunchAuvelity achieved over 24,000 new patient starts in the quarter, indicating strong market uptake.